CO6220856A2 - Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano - Google Patents
Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octanoInfo
- Publication number
- CO6220856A2 CO6220856A2 CO09089674A CO09089674A CO6220856A2 CO 6220856 A2 CO6220856 A2 CO 6220856A2 CO 09089674 A CO09089674 A CO 09089674A CO 09089674 A CO09089674 A CO 09089674A CO 6220856 A2 CO6220856 A2 CO 6220856A2
- Authority
- CO
- Colombia
- Prior art keywords
- crystalline
- salt form
- crystalline salt
- peaks
- forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
En la invención se provee una sal cristalina de sulfato de 3-endo-(8-{2-[ciclohexilmetil-((S)-2,3-dihidroxi-propionil)amino]etil}-8-aza-biciclo[3,2,1]oct-3-il)benzamida o un solvato de ésta. En la invención también se proveen composiciones farmacéuticas que comprenden estas formas de sales cristalinas, métodos para usar estas formas de sales cristalinas para tratar enfermedades asociadas con la actividad del receptor de opiáceos y procesos útiles para preparar estas formas de sales cristalinas. 1.- Una forma de sal cristalina que es la sal de sulfato de 3-endo-(8-{2-[ciclohexilmetil-((S)-2,3-dihidroxi-propionil)amino]etil}-8-aza-biciclo[3,2,1)oct-3-il)benzamida o un solvato de ésta.2.- La forma de sal cristalina de la reivindicación 1, donde la forma de sal cristalina es una sal cristalina de sulfato.3.- La forma de sal cristalina de la reivindicación 2, donde la forma de sal cristalina se caracteriza por un patrón de difracción de rayos X en polvo que tiene dos o más picos de difracción con valores 2? seleccionados entre6,58±0,20, 7,52±0,20, 9,35±0,20, 14,69±0,20, 16,01±0,20, 17,45±0,20, 17,99±0,20, 18,62±0,20, 19,76±0,20, 21,11±0,20, 22,07±0,20, 23,18±0,20, 23,74±0,20, 24,56±0,20, 25,63±0,20, 26,45±0,20, 27,86±0,20, 28,31±0,20, 29,54±0,20, 30,59±0,20, 31,58±0,20, 33,89±0,20 y 36,02±0,20.4.- La forma de sal cristalina de la reivindicación 3, donde el patrón de difracción de rayos X en polvo comprende dos o más picos de difracción con valores 2? seleccionados entre 14,69±0,20, 16,01±0,20, 21,11±0,20, 22,07±0,20 y 23,18±0,20.5.- La forma de sal cristalina de la reivindicación 2, donde la forma de sal cristalina se caracteriza por un patrón de difracción de rayos X en polvo donde las posiciones de los picos son sustancialmente acordes con las posiciones de los picos que se ilustran en la Figura 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90409007P | 2007-02-28 | 2007-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6220856A2 true CO6220856A2 (es) | 2010-11-19 |
Family
ID=39620376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09089674A CO6220856A2 (es) | 2007-02-28 | 2009-08-26 | Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US7943772B2 (es) |
| EP (1) | EP2132204B1 (es) |
| JP (2) | JP5512289B2 (es) |
| KR (1) | KR101480530B1 (es) |
| CN (1) | CN101616916B (es) |
| AR (2) | AR065554A1 (es) |
| AU (1) | AU2008219615B2 (es) |
| BR (1) | BRPI0807974B8 (es) |
| CA (1) | CA2678073C (es) |
| CL (1) | CL2008000573A1 (es) |
| CO (1) | CO6220856A2 (es) |
| CY (1) | CY1115077T1 (es) |
| DK (1) | DK2132204T3 (es) |
| ES (1) | ES2402031T3 (es) |
| HK (1) | HK1139399A1 (es) |
| HR (1) | HRP20130193T1 (es) |
| IL (1) | IL200131A (es) |
| MX (1) | MX2009009141A (es) |
| MY (1) | MY148318A (es) |
| NZ (1) | NZ578871A (es) |
| PL (1) | PL2132204T3 (es) |
| PT (1) | PT2132204E (es) |
| RU (1) | RU2458061C2 (es) |
| SI (1) | SI2132204T1 (es) |
| TW (1) | TWI409067B (es) |
| WO (1) | WO2008106159A1 (es) |
| ZA (1) | ZA200905832B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY145633A (en) * | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| TWI409067B (zh) * | 2007-02-28 | 2013-09-21 | Theravance Inc | ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型 |
| TWI415850B (zh) * | 2007-07-20 | 2013-11-21 | Theravance Inc | 製備ｍｕ類鴉片受體拮抗劑之中間物的方法 |
| US7691878B2 (en) * | 2007-08-27 | 2010-04-06 | Theravance, Inc. | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| TWI423801B (zh) * | 2007-08-27 | 2014-01-21 | Theravance Inc | 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物 |
| WO2009029252A1 (en) * | 2007-08-27 | 2009-03-05 | Theravance, Inc. | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| US7947710B2 (en) * | 2007-08-27 | 2011-05-24 | Theravance, Inc. | Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| WO2011035142A1 (en) * | 2009-09-18 | 2011-03-24 | Adolor Corporation | Use of opioid receptor antagonist for gastrointestinal tract disorders |
| KR20170132325A (ko) * | 2015-04-02 | 2017-12-01 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 뮤 오피오이드 수용체 길항제 및 오피오이드 제제의 조합 제형 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5159081A (en) * | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
| US6900228B1 (en) * | 1998-03-10 | 2005-05-31 | Research Triangle Institute | Opiate compounds, methods of making and methods of use |
| GB9810671D0 (en) * | 1998-05-18 | 1998-07-15 | Pfizer Ltd | Anti-pruritic agents |
| TWI244481B (en) * | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| GB9912410D0 (en) * | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| US6469030B2 (en) * | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
| US6467084B1 (en) * | 1999-12-16 | 2002-10-15 | Emware, Inc. | Systems and methods for reprogramming an embedded device with program code using relocatable program code |
| KR20030009376A (ko) | 2000-03-03 | 2003-01-29 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 3-(디아릴메틸렌)-8-아자비사이클로[3.2.1]옥탄 유도체 |
| US20020025948A1 (en) * | 2000-06-23 | 2002-02-28 | Banks Bernard Joseph | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| SI1440059T1 (sl) * | 2001-10-22 | 2008-08-31 | Pfizer Prod Inc | Derivati 3-azabiciklo(3.1.0)heksana kot antagonisti opioidnega receptorja |
| US7381721B2 (en) * | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| MXPA05011070A (es) * | 2003-04-14 | 2005-12-12 | Pfizer Prod Inc | Derivados de 3-azabiciclo [3.2.1] octano. |
| US7056930B2 (en) * | 2003-04-14 | 2006-06-06 | Pfizer Inc. | 2-Azabicyclo[3.3.1]nonane derivatives |
| US20040204453A1 (en) * | 2003-04-14 | 2004-10-14 | Pfizer Inc | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors |
| MXPA05011163A (es) | 2003-04-15 | 2005-12-14 | Pfizer Prod Inc | Derivados de 3-benzhidriliden-8-azabiciclo[3.2.1]octano con actividad de receptores opioides. |
| US6992090B2 (en) * | 2003-06-16 | 2006-01-31 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| US7435822B2 (en) | 2004-02-03 | 2008-10-14 | Janssen Pharmaceutica N.V. | 3-(diheteroarylmethylene)-8-azabicyclo[3.2.1]octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives |
| US7087749B2 (en) * | 2004-03-11 | 2006-08-08 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| MY145633A (en) * | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| JP2010509227A (ja) | 2006-11-07 | 2010-03-25 | ネクター セラピューティックス エイエル，コーポレイション | オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与 |
| TWI409067B (zh) * | 2007-02-28 | 2013-09-21 | Theravance Inc | ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型 |
-
2008
- 2008-02-15 TW TW097105472A patent/TWI409067B/zh active
- 2008-02-25 CL CL200800573A patent/CL2008000573A1/es unknown
- 2008-02-27 PL PL08726162T patent/PL2132204T3/pl unknown
- 2008-02-27 MY MYPI20093401A patent/MY148318A/en unknown
- 2008-02-27 BR BRPI0807974A patent/BRPI0807974B8/pt active IP Right Grant
- 2008-02-27 MX MX2009009141A patent/MX2009009141A/es active IP Right Grant
- 2008-02-27 AU AU2008219615A patent/AU2008219615B2/en active Active
- 2008-02-27 CN CN2008800059690A patent/CN101616916B/zh active Active
- 2008-02-27 EP EP08726162A patent/EP2132204B1/en active Active
- 2008-02-27 WO PCT/US2008/002583 patent/WO2008106159A1/en active Application Filing
- 2008-02-27 ES ES08726162T patent/ES2402031T3/es active Active
- 2008-02-27 KR KR1020097020094A patent/KR101480530B1/ko active IP Right Grant
- 2008-02-27 US US12/072,534 patent/US7943772B2/en active Active
- 2008-02-27 SI SI200830928T patent/SI2132204T1/sl unknown
- 2008-02-27 PT PT87261624T patent/PT2132204E/pt unknown
- 2008-02-27 NZ NZ578871A patent/NZ578871A/en not_active IP Right Cessation
- 2008-02-27 JP JP2009551709A patent/JP5512289B2/ja active Active
- 2008-02-27 DK DK08726162.4T patent/DK2132204T3/da active
- 2008-02-27 CA CA2678073A patent/CA2678073C/en active Active
- 2008-02-27 RU RU2009135834/04A patent/RU2458061C2/ru active
- 2008-02-28 AR ARP080100850A patent/AR065554A1/es not_active Application Discontinuation
-
2009
- 2009-07-29 IL IL200131A patent/IL200131A/en active IP Right Grant
- 2009-08-21 ZA ZA200905832A patent/ZA200905832B/xx unknown
- 2009-08-26 CO CO09089674A patent/CO6220856A2/es active IP Right Grant
-
2010
- 2010-06-15 HK HK10106008.5A patent/HK1139399A1/xx unknown
-
2011
- 2011-04-06 US US13/081,162 patent/US8247555B2/en active Active
-
2012
- 2012-07-17 US US13/550,781 patent/US8536335B2/en active Active
-
2013
- 2013-03-05 HR HRP20130193AT patent/HRP20130193T1/hr unknown
- 2013-04-08 CY CY20131100293T patent/CY1115077T1/el unknown
- 2013-05-10 JP JP2013099851A patent/JP2013151564A/ja not_active Withdrawn
- 2013-08-13 US US13/965,691 patent/US8816091B2/en active Active
-
2014
- 2014-07-16 US US14/333,003 patent/US9290491B2/en active Active
-
2016
- 2016-02-10 US US15/040,191 patent/US9949963B2/en active Active
-
2017
- 2017-07-31 AR ARP170102183A patent/AR109224A2/es unknown
-
2018
- 2018-03-13 US US15/919,678 patent/US10426766B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6220856A2 (es) | Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano | |
| UY29781A1 (es) | Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| PE20142353A1 (es) | Ansolvatos de sal de noribogaina | |
| CL2013002341A1 (es) | Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros | |
| CL2008002542A1 (es) | Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. | |
| CR20120002A (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| SV2010003567A (es) | Derivados bis-(sulfonilamino) en terapia 066 | |
| ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
| UY31069A1 (es) | Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones | |
| ECSP10010346A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis | |
| BR112014005389A8 (pt) | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| UY31554A1 (es) | Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus | |
| PE20071220A1 (es) | Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona y su proceso de preparacion | |
| AR047922A1 (es) | Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos | |
| BRPI0606199A2 (pt) | hidrocloreto de rimonabant, processo para a preparação de um hidrocloreto de rimonabant, composição farmacêutica, forma de dosagem farmacêutica, uso de um hidrocloreto de rimonabant e método de tratamento | |
| BR112022010377A2 (pt) | Novos tiromiméticos | |
| UY27850A1 (es) | Nuevos carbamatos de quinuclidina y composiciones farmacéuticas que los contienen | |
| CR20190144A (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos | |
| AR100369A1 (es) | Composición de dosis fija de formoterol y budesonide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |